GSK2256098 clinical trials
Also written GSK2256098.
How each study uses GSK2256098 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GSK2256098 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GSK2256098
- 4
Studies by the year they started
5 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
GlaxoSmithKline (3) · University Health Network, Toronto (1) · Alliance for Clinical Trials in Oncology (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses GSK2256098 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Written as FAK Inhibitor GSK2256098How we know
- A Study of GSK2256098 and Trametinib in Advanced Pancreatic CancerCompletedPhase 2University Health Network, TorontoNCT02428270Written as GSK2256098How we know
- A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT01938443Written as GSK2256098How we know
- Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT00996671Written as GSK2256098How we know
- Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT01138033Written as GSK2256098How we know
Codes
What other systems call GSK2256098 · ClinicalTrials.gg INT000301
- UNII (FDA) R7O0O4110GGSK-2256098Confirmed FDA, Wikidata
- Wikidata Q27077884GSK2256098Confirmed FDA, Wikidata
- NCI Thesaurus C88346FAK Inhibitor GSK2256098One source FDA
- DrugBank DB16106One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R7O0O4110G | GSK-2256098 | Confirmed FDA, Wikidata |
| Wikidata | Q27077884 | GSK2256098 | Confirmed FDA, Wikidata |
| NCI Thesaurus | C88346 | FAK Inhibitor GSK2256098 | One source FDA |
| DrugBank | DB16106 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.